8th -11th of January 2018: CEO Dr. John Ridden has been invited to attend the J.P. Morgan 36th Annual Healthcare Conference in San Francisco, California. John will be presenting Blueberry to a number of prospective [...]
Blueberry Therapeutics CSO David Cook presents at the first Royal Society Creating Connections conference, Research, industry and infrastructure in the North West, at Manchester's Museum of Science and Industry. David was invited to speak at this exciting event, [...]
John Ridden, CEO of Blueberry Therapeutics, recently presented at the UK-China Life Science Event run by the DIT (Department for International Trade). The event was hosted by Lancaster University and is an opportunity for [...]
Blueberry Therapeutics Ltd is pleased to announce that it has taken a significant step forward in the development of new Acne treatments by gaining support from Innovate UK to co-fund critical research of this [...]
Blueberry Therapeutics CEO John Ridden presented at the Biofocus 2017 event at the Centre for Life in Newcastle upon Tyne as part of the Industry Showcase session. The Biofocus event is an annual event bringing [...]
Blueberry Scientists Sarah Main and Julie Cook, attended the “Kinetics, Binding and Biophysics in Drug Discovery” workshop at The Mechanics Centre, Manchester on 27th June 2017. Attending the workshop will assist in current and future assay [...]
CSO David Cook attended the European Mediscience Awards Dinner in London as a guest of Zeus Capital. The Mediscience Awards recognize excellence in the Life Science sector and are held annually.
CSO David Cook presented at the recent ELRIG (European Laboratory Research & Innovation Group) held at Alderley Park. David presented as part of a diverse evening of seminars on the topic “Novel Approaches to Meeting [...]
Blueberry Therapeutics are pleased to announce they have dosed the first patient in a Phase I/II clinical trial of BB2603 in fungal infection of the skin and nail following successful regulatory and ethics approvals. The [...]
David gave a presentation to Manchester Metropolitan University as part of their Biomedical Away Day. His presentation was on the Opportunities and Challenges in collaborating between Universities and Industry.
Mike Davies, CMO and Co-founder, presented at the SMI Conference “Adaptive Designs in Clinical Trials” in London on 4th April 2017. In it, Mike described how Blueberry Therapeutics utilises adaptive clinical trial designs for its lead [...]
Blueberry's CEO John Ridden was interviewed by Times writer Michael Cape. John and Michael spoke about how Blueberry benefitted from AstraZeneca's move to Cambridge, which led to husband and wife team David and Julie [...]
The Blueberry Clinical Team, consisting of Dr Mike Davies, co-founder and Chief Medical Officer, Mark Sidaway, Clinical Project Manager and Jane Davies, Senior CRA, held their site initiation visit (SIV) at the Parexel Early [...]